Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Caris Life Sciences, Inc.
Report date June 20, 2025 · Filed June 23, 2025
Jointly reported with Carisome I, L.P.
Section 16 reporting ended · disclosed 2025-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 16,943,232 |
Reported balance
After 2025-06-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-06-20 · Conversion · Acquired 3,500,003 · Balance 16,943,232 F1: Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock. F2: The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein. F3: The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd.. |
| Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnotes | 0 |
Reported balance
After 2025-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-20 · Conversion · Disposed 14,000,000 · Balance 0 F1: Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock. F2: The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein. F3: The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd.. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock.
F2: The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F3: The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd..
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2025 Filed Jun 23, 2025 22:31 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | ConversionSeries A Preferred Stock · Derivative | 14,000,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-061805 · tm2518641-3_4seq1.xml · derivative · entry 2 ADAPT I Ltd. · CIK 0002072411 · 10% owner Carisome I, L.P. · CIK 0002072412 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,500,003 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock. F1 · derivative.exercise_date: Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock. F1 · derivative.expiration_date: Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock. F2 · ownership.nature: The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein. F3 · ownership.nature: The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd.. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 22:31 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | ConversionCommon Stock | 3,500,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061805 · tm2518641-3_4seq1.xml · nonDerivative · entry 1 ADAPT I Ltd. · CIK 0002072411 · 10% owner Carisome I, L.P. · CIK 0002072412 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 16,943,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock. F2 · ownership.nature: The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein. F3 · ownership.nature: The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd.. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.